1
Clinical Trials associated with QLS2312 / Not yet recruitingPhase 1 A Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of QLS2312 Injection in Chinese Healthy Adult Participants
This study is a first-in-human Phase 1 clinical study conducted in healthy adult participants in China to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of QLS2312 Injection after single and multiple subcutaneous administrations. The study consists of Part A and Part B: Part A is a single-ascending-dose study, and Part B is a multiple-ascending-dose (MAD) study.
100 Clinical Results associated with QLS2312
100 Translational Medicine associated with QLS2312
100 Patents (Medical) associated with QLS2312
100 Deals associated with QLS2312